-
Coron is full of firepower!
Time of Update: 2021-12-07
A few days ago, Kelun Pharmaceutical released the third quarter report, the company's performance has resumed growth, and innovation results have gradually emerged . According to data from Minaiwan
-
In-depth implementation of the Vaccine Management Law to ensure public health
Time of Update: 2021-12-07
On June 29, 2019, the 11th meeting of the Standing Committee of the 13th National People’s Congress passed the "People’s Republic of China Vaccine Management Law". On the same day, President Xi Jinp
-
Jichuan and other exclusive proprietary Chinese medicines are selling "magic medicine" endlessly!
Time of Update: 2021-12-07
In general, it is expected that the terminal Chinese patent medicine market in Guangzhou's physical pharmacies will rise to 5 billion yuan in 2021, with positive growth in 12 categories, and the overall situation is better than Beijing and Shanghai.
-
Merck meets its rivals!
Time of Update: 2021-12-07
com, the global sales of posaconazole in 2020 will exceed US$300 million, and the terminal of Chinese public medical institutions will increase by more than 90% year-on-year in 2021H1 .
The sales of terminal posaconazole in public medical institutions in China (unit: 100 million yuan) Source: Minet.
-
Solicit the "Measures for the Supervision and Administration of Drug Operation and Use Quality"
Time of Update: 2021-12-07
Improve the main body and responsibilities of MAH, strengthen supervision, and keep pace with the times On November 12, the official website of the State Food and Drug Administration posted a public notice soliciting opinions on the "Measures for the Supervision and Management of Drug Operation and Use Quality (Draft for Solicitation of Comments)" .
-
The next round of national mining: spine "wait more", trauma "take first"?
Time of Update: 2021-12-07
However, on November 12, the Tianjin Medical Purchasing Center issued a document "Notice on Carrying out Centralized Maintenance of Orthopedic Trauma Medical Consumables Information", which may indicate a change in the nationally sourced varieties .
-
2.7 billion varieties of octreotide acetate injection!
Time of Update: 2021-12-07
At present, there are still many companies whose supplementary applications for the consistency evaluation of octreotide acetate injection are under review, including Shanghai First Biochemical Pharmaceutical Co.
-
Multinational companies take measures to improve medical service capabilities to meet patient needs
Time of Update: 2021-12-07
Huang Jingxuan, head of GSK China’s core prescription drug business department, revealed: “In addition to epilepsy, we will also invest more in the field of bipolar disorder, including doctor education, to improve the level of disease diagnosis and treatment .
-
10 gynecological Chinese patent medicines "big sell" 9 exclusive varieties Baping
Time of Update: 2021-12-07
The latest data from Mi Nei. com shows that in the first half of 2021, China's public medical institutions' terminal gynecological Chinese patent medicine market sales increased by 5.
-
What was the third-quarter performance of vaccine stocks that instantly evaporated hundreds of billions of market value?
Time of Update: 2021-12-07
Chart 1: Source of operating income: From the financial data of the third quarter report on the company’s official website, CanSino’s net profit attributable to shareholders of listed companies in the first three quarters increased by 858.
-
National talks closing day: CAR-T corporate representatives did not show up, PD-1 "F4" stock prices fell
Time of Update: 2021-12-07
It is reported that representatives of Rongchang Biological Enterprise appeared at the negotiation site today, and the company's taltacept and vedicitumumab are the drugs that participated in the medical insurance negotiations for the first time .
-
Disaster reduction is a hot spot for the Chinese medicinal material market to enter a high-level adjustment stage!
Time of Update: 2021-12-07
The current market price of dog ridge is 15-16 yuan, which is not very good.
Recently, the supply of goods in the market has increased rapidly, and the price has risen.
-
Several hospitals in Fuzhou, Jiangxi Province were notified of illegal use of medical insurance funds
Time of Update: 2021-12-07
In accordance with the "Social Insurance Law of the People's Republic of China", "Regulations on the Supervision and Administration of the Use of Medical Security Funds" and "Service Agreements for Designated Medical Institutions", the Zixi County Medical Insurance Bureau recovered a total of 9100 yuan of illegal charges and ordered rectification within a time limit .
-
Insulin national procurement is approaching Ganli, Tonghua Dongbao, and the Federation can take the opportunity to win back the game?
Time of Update: 2021-12-07
International insulin giants Novo Nordisk, Eli Lilly, Sanofi and China's leading insulin companies Tonghua Dongbao, Tianmai Bio, Ganli Pharmaceutical, Zhuhai United Laboratories, Yuheng Pharmaceutical, Wanbang Biochemical and Dongyang Sun will compete on the same stage .
-
Mindray Anhui Collective: Performance is expected to double, ushering in a large number of foreign dealers to switch...
Time of Update: 2021-12-05
The impact of the centralized procurement of IVD in Anhui is not to suppress domestic IVD; Anhui is expected to double next year. It has contacted the medical insurance bureau and spent some time to
-
The future focus of Guangxi's traditional Chinese medicine industry should be on spices!
Time of Update: 2021-12-05
. The planting area of Luo Han Guo this year is the same as last year, but this year's production has been significantly reduced, resulting in lower output than last year; coupled with inventory digestion, and the continuous development of new application areas for Luo Han Guo, it has also stimulated the increase in annual demand and consumption .
-
$2 Billion Oral Psoriasis "Fighting"!
Time of Update: 2021-12-05
According to data from Meinenet, the global sales of Apomilast tablets in 2020 will exceed US$2 billion .
Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangxi Qingfeng Pharmaceutical and other eight companies have submitted listing applications under the new classification for review and approval .
-
Vaccines + specific drugs, can the new crown epidemic end?
Time of Update: 2021-12-05
"News 1+1" invited Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, and Peking University professor Xie Xiaoliang, to pay attention to: vaccine + specific drugs, can the new crown epidemic end?
-
Medical anti-corruption upgrade: online and offline full compliance!
Time of Update: 2021-12-05
A few days ago, the National Health Commission, the National Medical Insurance Administration, and the State Administration of Traditional Chinese Medicine jointly issued the "Nine Guidelines for the
-
Do you have to "lie flat" in the face of centralized procurement of original research pharmaceutical companies?
Time of Update: 2021-12-05
We selected 5 original research companies (Bayer, Merck, Boehringer Ingelheim, Sanofi and Squibb) related to the first and second batches of centralized procurement regulations, and analyzed 15 related original research products of these companies (see Table 1) The overall market and retail performance .
